P ia, a 9-month-old baby with spinal muscular atrophy, was the first patient to receive Zolgensma gene therapy in Belgium. The product was injected on 9 October 2019, 3 weeks after an unprecedented crowdfunding campaign that raised €1.9 million in a few days. It was a last-resort initiative launched by Pia's parents after the Belgian health payer denied reimbursement because the product was not yet approved by the European Medicines Agency (EMA). Doctors of another Belgian child with adenosine deaminase deficiency (ADA-SCID) have not succeeded in obtaining reimbursement for EMA-approved Strimvelis, the gene therapy product that represents the best possible therapeutic option for this child. Such situations will be faced by increasing numbers of patients who could benefit from either ex-vivo retrovirally mediated or in vivo adeno-associated viral vectormediated gene transfer 1 . The number of products based on gene therapy on the market or in the pipeline-for the treatment of common diseases such as β-thalassemia, sickle cell disease and hemophilia, or autologous chimeric antigen receptor (CAR) T cells for leukemia and lymphomacontinues to grow. However, the cost of these potentially lifesaving therapies is prohibitive for most patients, and this is true on a worldwide scale, regardless of the healthcare system (Table 1) . Indeed, although the European Union preceded the United States in approving the first gene therapies, it has yet to put a system in place to provide affordable access to these treatments. The clinical applications of genome editing relying on engineered nucleases or baseediting enzymes that are under development will most likely raise the same issues.
To address this conundrum, gene therapy manufacturers, together with several health economists and policymakers, are developing the so-called value-based model principle, whereby the price of the therapy is estimated as a measure of the value it brings to patients and society. However, as clearly stated by the Institute for Clinical and Economic Review in its Summit Policy Report 2 , valuebased pricing should only be used as a ceiling reference during the negotiations between manufacturers and payers to set actual prices. The latter should aim at maximizing access to patients while offering market-consistent innovation incentives to gene therapy firms. But when there is no or little competition, as is the case with gene therapies, health systems and payers have little negotiating power, leaving companies in a position to enhance their profits by setting the maximum pricing for their therapies as the market norm. Moreover, the fact that prices are usually set according to the accepted value of similar products already on the market further contributes to gene therapies' exorbitant prices, as argued by Peter Bach 3 . Concretely, even if a $2 million price per patient would be consistent with a value-based ceiling price, the negotiated price should not go beyond covering R&D and manufacturing and distribution costs, plus a market-consistent return for shareholders.
Several political actions are underway toward better regulation of drug pricing. In the United States, ongoing political debate around this topic might lead to the reintroduction of the 'reasonable pricing' clauses in technology transfer agreements between academia and industry, a policy established by the National Institutes of Health in 1989, only to be withdrawn a few years later under pressure from industrial lobbies 4 . The World Health Organization recently attempted to promote increased transparency of prices for medicines, vaccines and other health products by recommending that member states publicly share information on the actual prices. In European countries where healthcare costs are covered by payers controlled by public authorities, prices are subject to negotiations between governments and pharmaceutical industries, the contents of which are not currently disclosed to the public. The resolution, accepted 28 May 2019 5 , might increase transparency, but its impact will remain limited by its nonbinding status. Efforts by some EU member states-Belgium, the Netherlands, Austria, Ireland and Luxembourg-to join forces in pricing negotiations with drug companies (http://www.beneluxa.org) should put these actors in a better position to require more transparency about R&D, manufacturing and distribution costs of the drug, but will most likely have a meaningful impact only if other, larger countries adhere to such common policy.
Although pertinent and welcome, these measures alone are unlikely to solve the current price conundrum, as they focus on regulating the status quo rather than promoting a credible shift in the behavior of biopharmaceutical firms marketing gene therapy products. In our view, corporations must be encouraged to enact a meaningful change in their governance. As long as gene therapy companies see return on shareholder investment as their sole objective, consistent with their fiduciary responsibility, pricing will continue to tip upward on the valuebased pricing scale.
Change could be enacted by leveraging companies' corporate social responsibility. We propose that payers incentivize companies involved in gene therapy to create ad hoc subsidiaries for these activities and organize them according to the Benefit Corporation concept 6 in order to subsequently obtain a B Corporation certification (https://bcorporation.net/). The Benefit Corporation declaration gives legal protection to companies to pursue social and environmental performance as well as value for shareholders. The boards of Benefit Corporations are required to consider other stakeholders, in addition to shareholders, in their decision-making. The application for a B corporate certification further comment enhances accountability to social good, as the certification is done by an external third party based on the company's verified performance on the B Impact Assessment, making the Benefit Corporation a certified B corporation.
By acquiring the status of certified B corporation, gene therapy companies should be able to leverage the social impact of their pricing in their performance indicators, thus affording them the opportunity to bring their pricing down to a 'market-consistent' level in order to enhance their social performance. Incentivizing large pharma companies to create subsidiaries with a B Corporation status for their gene therapy activities would follow the example of Unilever with Ben & Jerry's or Danone with multiple subsidiaries.
Pushback is to be expected. But corporations themselves are recognizing the value in generating long-term value for all stakeholders instead of only for shareholders as well as in shifting their priorities from profit maximization to optimizing value creation, as demonstrated by the latest iteration of the Business Roundtable's Statement on the Purpose of a Corporation 7 and in the Value Balancing Alliance (https://www.value-balancing.com), both of which pharmaceutical companies are signatories to. The next step would be for payers to consider making reimbursement of gene therapy products conditional on their commercialization by certified B Corporations. The greater objective should be a pricing policy that results from a credible alignment of industry, patients and payers' interests. ❐ Alain Fischer 1 *, Mathias Dewatripont 2,3 and Michel Goldman 3 * 
